Literature DB >> 29622625

Lipid-Lowering Agents and High HDL (High-Density Lipoprotein) Are Inversely Associated With Intracranial Aneurysm Rupture.

Anil Can1, Victor M Castro2, Dmitriy Dligach3,4, Sean Finan3, Sheng Yu5,6, Vivian Gainer2, Nancy A Shadick7, Guergana Savova3, Shawn Murphy2,8, Tianxi Cai9, Scott T Weiss5,10, Rose Du11,10.   

Abstract

BACKGROUND AND
PURPOSE: Growing evidence from experimental animal models and clinical studies suggests the protective effect of statin use against rupture of intracranial aneurysms; however, results from large studies detailing the relationship between intracranial aneurysm rupture and total cholesterol, HDL (high-density lipoprotein), LDL (low-density lipoprotein), and lipid-lowering agent use are lacking.
METHODS: The medical records of 4701 patients with 6411 intracranial aneurysms diagnosed at the Massachusetts General Hospital and the Brigham and Women's Hospital between 1990 and 2016 were reviewed and analyzed. Patients were separated into ruptured and nonruptured groups. Univariable and multivariable logistic regression analyses were performed to determine the effects of lipids (total cholesterol, LDL, and HDL) and lipid-lowering medications on intracranial aneurysm rupture risk. Propensity score weighting was used to account for differences in baseline characteristics of the cohorts.
RESULTS: Lipid-lowering agent use was significantly inversely associated with rupture status (odds ratio, 0.58; 95% confidence interval, 0.47-0.71). In a subgroup analysis of complete cases that includes both lipid-lowering agent use and lipid values, higher HDL levels (odds ratio, 0.95; 95% confidence interval, 0.93-0.98) and lipid-lowering agent use (odds ratio, 0.41; 95% confidence interval, 0.23-0.73) were both significantly and inversely associated with rupture status, whereas total cholesterol and LDL levels were not significant. A monotonic exposure-response curve between HDL levels and risk of aneurysmal rupture was obtained.
CONCLUSIONS: Higher HDL values and the use of lipid-lowering agents are significantly inversely associated with ruptured intracranial aneurysms.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  aneurysm; cholesterol; intracranial aneurysms; lipids; subarachnoid hemorrhage

Mesh:

Substances:

Year:  2018        PMID: 29622625      PMCID: PMC5915939          DOI: 10.1161/STROKEAHA.117.019972

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

Review 1.  Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2005-09-05       Impact factor: 2.778

2.  Risk factors for the formation and rupture of intracranial saccular aneurysms in Shimane, Japan.

Authors:  Tetsuji Inagawa
Journal:  World Neurosurg       Date:  2009-08-07       Impact factor: 2.104

3.  Risk factors for aneurysmal subarachnoid hemorrhage - BMI and serum lipids: 11-year follow-up of the HUNT and the Tromsø Study in Norway.

Authors:  M S Sandvei; H Lindekleiv; P R Romundstad; T B Müller; L J Vatten; T Ingebrigtsen; I Njølstad; E B Mathiesen; A Vik
Journal:  Acta Neurol Scand       Date:  2011-07-28       Impact factor: 3.209

4.  Serum lipids as protective factors for subarachnoid hemorrhage.

Authors:  Yasuharu Tokuda; Gerald H Stein
Journal:  J Clin Neurosci       Date:  2005-06       Impact factor: 1.961

5.  Total and high-density lipoprotein cholesterol and stroke risk.

Authors:  Yurong Zhang; Jaakko Tuomilehto; Pekka Jousilahti; Yujie Wang; Riitta Antikainen; Gang Hu
Journal:  Stroke       Date:  2012-04-10       Impact factor: 7.914

6.  Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women.

Authors:  O Gatchev; L Råstam; G Lindberg; B Gullberg; G A Eklund; S O Isacsson
Journal:  Ann Epidemiol       Date:  1993-07       Impact factor: 3.797

7.  Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification.

Authors:  Monique H M Vlak; Gabriel J E Rinkel; Paut Greebe; Jacoba P Greving; Ale Algra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-25       Impact factor: 10.154

8.  Major risk factors for aneurysmal subarachnoid hemorrhage in the young are modifiable.

Authors:  Joseph P Broderick; Catherine M Viscoli; Thomas Brott; Walter N Kernan; Lawrence M Brass; Edward Feldmann; Lewis B Morgenstern; Janet Lee Wilterdink; Ralph I Horwitz
Journal:  Stroke       Date:  2003-05-22       Impact factor: 7.914

9.  Risk factors for subarachnoid hemorrhage in a longitudinal population study.

Authors:  P Knekt; A Reunanen; K Aho; M Heliövaara; A Rissanen; A Aromaa; O Impivaara
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

10.  Risk factors for hemorrhagic stroke in Wonju, Korea.

Authors:  J K Park; H J Kim; S J Chang; S B Koh; S Y Koh
Journal:  Yonsei Med J       Date:  1998-06       Impact factor: 2.759

View more
  16 in total

1.  Inverse Association Between HDL (High-Density Lipoprotein) Cholesterol and Stroke Risk Among Patients With Type 2 Diabetes Mellitus.

Authors:  Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

2.  Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

Authors:  Irina M Sanchis; Shehbaz Shukoor; Maria V Irazabal; Charles D Madsen; Fouad T Chebib; Marie C Hogan; Ziad El-Zoghby; Peter C Harris; John Huston; Robert D Brown; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2019-07-30       Impact factor: 8.237

Review 3.  Disturbed flow's impact on cellular changes indicative of vascular aneurysm initiation, expansion, and rupture: A pathological and methodological review.

Authors:  Kevin Sunderland; Jingfeng Jiang; Feng Zhao
Journal:  J Cell Physiol       Date:  2021-09-06       Impact factor: 6.384

4.  Associations Between Drug Treatments and the Risk of Aneurysmal Subarachnoid Hemorrhage: a Systematic Review and Meta-analysis.

Authors:  Kampei Shimizu; Tomohiro Aoki; Nima Etminan; Katharina A M Hackenberg; Shoichi Tani; Hirotoshi Imamura; Hiroharu Kataoka; Nobuyuki Sakai
Journal:  Transl Stroke Res       Date:  2022-10-15       Impact factor: 6.800

5.  A preliminary investigation of radiomics differences between ruptured and unruptured intracranial aneurysms.

Authors:  Chubin Ou; Winston Chong; Chuan-Zhi Duan; Xin Zhang; Michael Morgan; Yi Qian
Journal:  Eur Radiol       Date:  2020-10-14       Impact factor: 5.315

6.  An association of low high-density lipoprotein levels with recurrence of chronic subdural hematoma.

Authors:  Wen-Chao Liu; Qing-Qing Lin; Jing Jin; Ming Wang; Wen-Dong You; Jun Gu; Jian-Wei Pan
Journal:  Acta Neurochir (Wien)       Date:  2020-11-04       Impact factor: 2.216

7.  Decreased Total Iron Binding Capacity May Correlate with Ruptured Intracranial Aneurysms.

Authors:  Anil Can; Pui Man Rosalind Lai; Victor M Castro; Sheng Yu; Dmitriy Dligach; Sean Finan; Vivian Gainer; Nancy A Shadick; Guergana Savova; Shawn Murphy; Tianxi Cai; Scott T Weiss; Rose Du
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

8.  Testosterone aggravates cerebral vascular injury by reducing plasma HDL levels.

Authors:  Tao Jin; Lu Wang; Dongbo Li; Tao Yang; Yuefei Zhou
Journal:  Open Life Sci       Date:  2020-12-31       Impact factor: 0.938

9.  Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture.

Authors:  Mikel Terceño; Sebastian Remollo; Yolanda Silva; Saima Bashir; Mariano Werner; Víctor A Vera-Monge; Joaquín Serena; Carlos Castaño
Journal:  PLoS One       Date:  2021-02-18       Impact factor: 3.240

Review 10.  The Association between Genes Polymorphisms of Heparan Sulfate Proteoglycan 2 (HSPG2) and Chondroitin Sulfate Proteoglycan 2 (CSPG2) and Intracranial Aneurysm Susceptibility: A Meta-Analysis.

Authors:  Huahui Liu; Wen Huang
Journal:  Iran J Public Health       Date:  2019-11       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.